OmniGuide, Inc. develops advanced energy surgical products for minimally invasive surgery, laparoscopy, and robotic-assisted surgery applications. Its solutions include BeamPath ENT System, a fiber and instrumentation solution customized for head and neck surgeons, laryngologists, and otolaryngologists; BeamPath GYN system that provides disease removal solutions for gynecologists; FELS-25A Intelliguide laser system, a precision CO2 laser combined with a flexible fiber beam delivery system; BeamPath Robotic Fiber and FlexGuideULTRA that work in tandem with the robotic platform to deliver CO2 laser energy in a minimally invasive approach; and BeamPath OTO System, which provides otologists with...
4 Maguire Road
Lexington, MA 02421
Founded in 2000
OmniGuide Surgical Announces Commercial Launch of VELOCITY High Performance CO2 Laser Fiber
Mar 15 17
OmniGuide Holdings, Inc. announced the full commercial release of its VELOCITY High Performance Fiber. VELOCITY is the latest addition to OmniGuide's advanced surgical energy platform and is designed to provide precision cutting with increased speed and performance while maintaining OmniGuide's commitment to patient safety. With VELOCITY, the fibers have been developed for higher performance by increasing the mirror content to twelve distinct layers, which serve to increase wattage output and ultimately the cutting speed. With cutting speed now equivalent to monopolar electrosurgery, surgeons can reduce procedure time while maintaining micron-level thermal spread and the tissue preservation benefits associated with CO2 energy. Another design improvement of the VELOCITY High Performance Fiber is that the hollow inner-core has been expanded to enable the newly increased energy transmission to be sustainable throughout the surgical case. This specific design modification preserves the integrity of the higher speed CO2 laser transmission, making it applicable to a wider variety of open, laparoscopic and robotic procedures across multiple surgical specialties.
OmniGuide Holdings, Inc. Announces Management Appointments
Nov 10 16
OmniGuide Holdings, Inc. announced the appointment of John Markovich as CFO. The company also named Ajay Bhave as VP of Operations and John Barnhill as VP of Marketing /Business Development. The addition of Markovich, Bhave and Barnhill follows the recent appointment of new President and CEO John T. Buhler and the company’s recently announced merger with Domain Surgical, which complements OmniGuide Surgical’s leadership in flexible fiber CO2 laser surgery by offering electrically silent ferromagnetic technology that has been clinically proven to precisely cut, coagulate and seal tissue. Reporting to Buhler, Markovich as CFO will be oversee the company’s overall financial operations. Markovich has over 25 years of diverse financial leadership experience, which includes directing multiple privately-held startups and several public companies, including a NYSE-listed Fortune 500 multi-national, in both the healthcare and technology industries. Previously, Markovich held CFO positions with Veritone, Inc., NanoH20, Inc., EMCORE Corporation and Orqis Medical, Inc. Bhave, who as part of OmniGuide Holdings senior staff, will be responsible for the company’s Global Operations, including manufacturing and the integration of Domain Surgical. Prior to joining OmniGuide Holdings, Inc., Bhave held the position of Corporate VP of Global Engineering with Natus Medical Inc., with responsibility for all aspects of new product development. Prior to Natus, he held a number of senior management positions, including global supply chain and plant management, during his 21 years with General Electric Healthcare. Barnhill will be responsible for global marketing efforts and business development strategy. Previously, Barnhill held a similar position with RF Surgical, Inc., an early-stage medical technology company that was recently acquired by Medtronic. Prior to that, Barnhill was with Edwards Lifesciences where he held several global marketing and medical education positions within both the Heart Valve Therapy and Critical Care franchises. Barnhill also held a marketing leadership position with SenoRx, where he grew the company’s breast cancer therapy portfolio, contributing to the successful exit of the company. He will also report to Buhler.